SynCore Biotechnology Co.,Ltd (4192.TWO)
- Previous Close
47.80 - Open
48.15 - Bid 52.50 x --
- Ask --
- Day's Range
48.15 - 52.50 - 52 Week Range
34.55 - 73.51 - Volume
269,246 - Avg. Volume
47,418 - Market Cap (intraday)
1.846B - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-1.19 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts; and SB04,an conventional drug for the treatment of age-related macular degeneration that is in Phase II clinical trials. In addition, the company provides SB05-EndoTAG, an conventional drug for pancreatic cancer and triple-negative breast cancer that is in Phase III clinical trials. Further, it distributes cameras under the epiCam name that is used in recording the progress of ophthalmology diseases. The company has partnerships with Medigene AG and MacuCLEAR Inc.; Sinphar Pharmaceutical Co., Ltd.; and The National Health Research Institutes. SynCore Biotechnology Co.,Ltd was incorporated in 2008 and is headquartered in Yilan City, Taiwan. The company is a subsidiary of Sinphar Pharmaceutical Co., Ltd.
www.syncorebio.comRelated News
Performance Overview: 4192.TWO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4192.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4192.TWO
Valuation Measures
Market Cap
1.85B
Enterprise Value
1.58B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
91.41
Price/Book (mrq)
5.17
Enterprise Value/Revenue
78.08
Enterprise Value/EBITDA
-88.96
Financial Highlights
Profitability and Income Statement
Profit Margin
-189.01%
Return on Assets (ttm)
-6.98%
Return on Equity (ttm)
-12.60%
Revenue (ttm)
20.2M
Net Income Avi to Common (ttm)
-38.17M
Diluted EPS (ttm)
-1.19
Balance Sheet and Cash Flow
Total Cash (mrq)
271.36M
Total Debt/Equity (mrq)
0.55%
Levered Free Cash Flow (ttm)
-73.89M
Company Insights: 4192.TWO
4192.TWO does not have Company Insights